MedTrace Logo

Direct Observation Study of Kratom Product Effects Among Regular Consumers

NCT06089980 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2026-01-23

No results posted yet for this study

Summary

The goal of this observational clinical study is to is to learn more about how commercial kratom products affect healthy adults who consume them regularly. The main questions it aims to answer are:

1. What are the acute physiological, subjective, and cognitive effects of kratom following participant self-administration of a single oral dose of the participants usual kratom product at the participants typical dose?
2. What are the physiological, subjective, and cognitive effects associated with kratom product discontinuation among adults who use regularly?
3. What are the pharmacokinetics of kratom products consumed by adults who use regularly? On the first study day: Under direct observation, participants will self-administer a single oral dose of the participants own commercial kratom product that that is regularly taken and will consume it at the participants self-selected typical dose/serving. Following this, serial blood draws and urine collection will occur along with administration of validated questionnaires, tests, and continual monitoring. After this first study day, participants will no longer be permitted to use any of the participants kratom product during the study. On study nights/days 2-3: participants will reside a clinical research unit and be observed and evaluated for kratom withdrawal syndrome.

Conditions

  • Kratom Pharmacokinetics
  • Kratom Pharmacodynamics
  • Kratom

Interventions

BEHAVIORAL

Effects from acute kratom exposure

Participants who regularly use commercial Kratom products will orally consume a known quantity of kratom under direct observation on first study day; following this, participants will stop kratom use for approximately 2 nights and 2.5 days for the duration of the study.

Sponsors & Collaborators

  • University of Florida

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Kirsten E Smith, Ph.D. · Johns Hopkins University

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2028-02-29
Completion
2028-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06089980 on ClinicalTrials.gov